Ocata Therapeutics Inc fka OCAT

[chuckanutman]

http://www.nasdaq.com/article/fprx-gets-high-five-clrx-put-on-notice-rna-snapped-up-natesto-changes-hands-20141125-00006#ixzz3KHuitXMj

Ocata Therapeutics Inc. (OCAT.OB) has been granted Advanced Therapy Medicinal Product designation for its RPE therapy for macular degeneration by the European Medicines Agency.

The RPE, or retinal pigment epithelium, is a highly specialized tissue that is located between the choroids and the neural retina.

Ocata reported positive results from phase 1/2 clinical trials of RPE cells for the treatment of Stargardt's macular degeneration and dry age-related macular degeneration last month.

The company is preparing to dose the first patient in a phase II trial for Stargardt's patients by the end of this year.